Pharmacokinetics of nadolol in children with supraventricular tachycardia

J Clin Pharmacol. 1992 Nov;32(11):1023-7. doi: 10.1002/j.1552-4604.1992.tb03805.x.


The pharmacokinetics of intravenous and oral nadolol, a long-acting beta-adrenoceptor blocking agent, were investigated in six children receiving the drug for treatment of supraventricular tachycardia. In the youngest patient (age 3 months), no distribution phase was seen. In children younger than 22 months of age, nadolol is more rapidly eliminated (t1/2 = 4.3 hours or less) than in older children, in whom elimination is more similar to that in adults (t1/2 approximately 7.3-15.7 hours). After intravenous administration, nadolol displayed two-compartment pharmacokinetics with a distribution phase (t1/2 = 0.2-1.1 hours) followed by elimination. Large changes in nadolol pharmacokinetics may occur during the first year of life. Nadolol should be used cautiously in infants.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Nadolol / pharmacokinetics*
  • Nadolol / therapeutic use
  • Tachycardia, Supraventricular / drug therapy
  • Tachycardia, Supraventricular / metabolism*


  • Nadolol